Peregrine Capital Management LLC raised its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 13.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 760,157 shares of the company’s stock after acquiring an additional 92,623 shares during the period. HealthEquity comprises approximately 0.9% of Peregrine Capital Management LLC’s portfolio, making the stock its 12th biggest holding. Peregrine Capital Management LLC owned about 1.26% of HealthEquity worth $38,449,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the business. New England Research & Management Inc. increased its holdings in HealthEquity by 109.6% in the 3rd quarter. New England Research & Management Inc. now owns 15,010 shares of the company’s stock worth $759,000 after buying an additional 7,850 shares in the last quarter. First Trust Advisors LP lifted its position in shares of HealthEquity by 23.6% during the 3rd quarter. First Trust Advisors LP now owns 116,500 shares of the company’s stock valued at $5,893,000 after buying an additional 22,217 shares in the last quarter. Nationwide Fund Advisors lifted its position in shares of HealthEquity by 40.3% during the 3rd quarter. Nationwide Fund Advisors now owns 270,024 shares of the company’s stock valued at $13,658,000 after buying an additional 77,630 shares in the last quarter. Sanders Morris Harris LLC purchased a new position in shares of HealthEquity during the 3rd quarter valued at about $2,301,000. Finally, Wasatch Advisors Inc. lifted its holdings in HealthEquity by 2.2% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,442,180 shares of the company’s stock worth $121,694,000 after purchasing an additional 52,885 shares in the last quarter. 91.75% of the stock is owned by institutional investors and hedge funds.
In other news, VP Jon Soldan sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $40.68, for a total value of $1,017,000.00. Following the transaction, the vice president now owns 30,652 shares in the company, valued at approximately $1,246,923.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Frank Medici sold 32,404 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $51.09, for a total value of $1,655,520.36. Following the sale, the director now owns 6,381 shares in the company, valued at $326,005.29. The disclosure for this sale can be found here. Insiders have sold 1,563,591 shares of company stock worth $81,519,756 in the last quarter. Company insiders own 19.00% of the company’s stock.
HealthEquity, Inc. (HQY) traded up $0.31 during midday trading on Tuesday, reaching $50.05. The company’s stock had a trading volume of 223,800 shares, compared to its average volume of 536,618. HealthEquity, Inc. has a 52 week low of $37.62 and a 52 week high of $55.31. The firm has a market cap of $3,008.71, a PE ratio of 78.95, a price-to-earnings-growth ratio of 2.18 and a beta of 1.77.
HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The company had revenue of $56.90 million for the quarter, compared to analyst estimates of $55.66 million. During the same quarter in the prior year, the company posted $0.16 EPS. The business’s revenue for the quarter was up 28.7% compared to the same quarter last year. equities research analysts forecast that HealthEquity, Inc. will post 0.7 EPS for the current year.
A number of research analysts recently commented on HQY shares. TheStreet raised HealthEquity from a “c” rating to a “b” rating in a report on Monday, July 31st. Cantor Fitzgerald reiterated a “buy” rating and issued a $56.00 target price on shares of HealthEquity in a report on Monday, September 25th. Zacks Investment Research upgraded HealthEquity from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Wednesday, October 11th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $61.00 target price on shares of HealthEquity in a research report on Wednesday, September 6th. Finally, BidaskClub lowered HealthEquity from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $57.50.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.